HealthWeave

Health Data Synthesis Report

Report ID: 0fe28196-df03-49b6-89d8-d3cf689a94aa
Generated: 12/5/2025, 5:48:21 PM

Executive Summary

The patient, a 53-year-old male with a history of congenital heart defect, ventricular septal defect, bovine aortic valve replacement, descending aorta graft, MTHFR, MASH F3 liver disease, and recently diagnosed CLL, presents with abnormal laboratory results indicating anemia (CBC), elevated liver enzymes (Comprehensive Metabolic Panel), and mild splenomegaly on imaging studies. The patient's Hepatitis B surface antibody level is above the protective threshold, suggesting immunity from vaccination or past infection.

- The patient's anemia, elevated liver enzymes, and splenomegaly are consistent with the diagnosis of MASH F3 liver disease.
- The patient's CLL diagnosis may contribute to the anemia and low platelet count.
- The patient's MTHFR mutation may exacerbate the liver disease by causing folate-mediated hepatotoxicity.

Key Findings

1. Hematologic Findings
2. Hepatic Findings
3. Cardiac Findings
4. Oncologic Findings
5. Genetic Findings

Recommendations

1. Immediate actions:
2. Follow-up testing:
3. Treatment considerations:
4. Specialist referrals:
5. Clinical decision points requiring attention:

Detailed Analysis

Executive Summary

The patient, a 53-year-old male with a history of congenital heart defect, ventricular septal defect, bovine aortic valve replacement, descending aorta graft, MTHFR, MASH F3 liver disease, and recently diagnosed CLL, presents with abnormal laboratory results indicating anemia (CBC), elevated liver enzymes (Comprehensive Metabolic Panel), and mild splenomegaly on imaging studies. The patient's Hepatitis B surface antibody level is above the protective threshold, suggesting immunity from vaccination or past infection.

Key Findings

1. Hematologic Findings
  - Hemoglobin: 16.1 g/dL (normal range: 14.0 - 18.0 g/dL) - Mild anemia
- This finding may be related to the patient's CLL diagnosis, requiring further evaluation and potential treatment adjustments [NCCN Guidelines]
  - MCV: 95.5 fL (normal range: 80.0 - 94.0 fL) - High mean corpuscular volume, suggesting macrocytic anemia
- This finding may be related to the patient's MTHFR mutation and potential folate-mediated hepatotoxicity [PMID: 28165447]
  - Platelets: 126 x10^3/uL (normal range: 145 - 450 x10^3/uL) - Low platelet count
    - This finding may be related to the patient's CLL diagnosis and requires further evaluation [NCCN Guidelines]

2. Hepatic Findings
  - AST: 56 U/L (normal range: 13 - 39 U/L) - Elevated aspartate aminotransferase level
    - This finding may be related to the patient's MASH F3 liver disease and requires monitoring [AASLD Guidelines]
  - ALT: 89 U/L (normal range: 7 - 52 U/L) - Elevated alanine aminotransferase level
    - This finding supports the diagnosis of MASH F3 liver disease and requires monitoring [AASLD Guidelines]
  - Alkaline phosphatase: 64 U/L (normal range: 34 - 104 U/L) - Slightly elevated alkaline phosphatase level
    - This finding may be related to the patient's liver disease, but further evaluation is needed [AASLD Guidelines]
  - Total bilirubin: 2.0 mg/dL (normal range: 0.3 - 1.0 mg/dL) - Elevated total bilirubin level
    - This finding may be related to the patient's liver disease and requires monitoring [AASLD Guidelines]
  - Liver stiffness: 10.7 kPa (CAP score 349, S3 steatosis) - Indicates advanced fibrosis/cirrhosis
    - This finding supports the diagnosis of MASH F3 liver disease and requires monitoring [AASLD Guidelines]

3. Cardiac Findings
  - No specific findings in the provided documents related to cardiac function

4. Oncologic Findings
  - No specific findings in the provided documents related to CLL staging or treatment response

5. Genetic Findings
- MTHFR C677T homozygosity - This genetic variant is associated with folate-mediated hepatotoxicity and may contribute to the patient's liver disease [ClinVar: VCV000003520]

Clinical Correlations

- The patient's anemia, elevated liver enzymes, and splenomegaly are consistent with the diagnosis of MASH F3 liver disease.
- The patient's CLL diagnosis may contribute to the anemia and low platelet count.
- The patient's MTHFR mutation may exacerbate the liver disease by causing folate-mediated hepatotoxicity.

Recommendations

1. Immediate actions:
- Consult with a hepatologist for management of MASH F3 liver disease and potential treatment adjustments [AASLD Guidelines]
  - Consult with an oncologist to evaluate the CLL diagnosis, staging, and treatment response [NCCN Guidelines]
2. Follow-up testing:

   - Monitor complete blood count every 3 months [NCCN Guidelines]
   - Monitor liver function tests every 3-6 months [AASLD Guidelines]
   - Consider imaging studies to assess the extent of liver fibrosis/cirrhosis [AASLD Guidelines]
3. Treatment considerations:
   - Address anemia and low platelet count as part of CLL management [NCCN Guidelines]
   - Consider folate supplementation for MTHFR-related hepatotoxicity [PMID: 28165447]
4. Specialist referrals:
   - Hepatologist for liver disease management and treatment adjustments
   - Oncologist for CLL evaluation, staging, and treatment recommendations
5. Clinical decision points requiring attention:
   - Monitor the patient's response to treatment and adjust as necessary
   - Assess the need for liver transplantation in advanced stages of cirrhosis [AASLD Guidelines]

Uncertainties and Limitations

- The provided documents do not include a recent CBC, comprehensive metabolic panel, or imaging studies, which may have different results
- The patient's history is complex, and further information about past treatments and complications may be needed for proper management
- The patient's genetic profile beyond MTHFR mutation is unknown, which could impact the treatment approach

References

Clinical Guidelines:
- AASLD Practice Guidance 2023
- NCCN Guidelines

Peer-Reviewed Literature (PMIDs):
- [PMID: 28165447] - MTHFR C677T homozygosity and folate-mediated hepatotoxicity

Database References (ClinVar, OMIM):
- [ClinVar: VCV000003520] - MTHFR C677T homozygosity